TY - JOUR
T1 - Radiobiology of Radioimmunotherapy with 90Y Ibritumomab Tiuxetan (Zevalin)
AU - Hernandez, M. Carmen
AU - Knox, Susan J.
N1 - Funding Information:
Dr Knox has received research grant support from Biogen Idec Inc.
PY - 2003/12
Y1 - 2003/12
N2 - Radioimmunotherapy represents a significant advance over unlabeled immunotherapy for the treatment of patients with B-cell non-Hodgkin's lymphoma. The efficacy of radioimmunotherapeutic agents depends in large part on the basic biological effects associated with their components, monoclonal antibodies and radionuclides, separately and in combination. The radiobiological effects associated with yttrium 90-labeled ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA) include the induction of apoptosis and cell-cycle redistribution (eg, arrest of cells in the G2/M phase of the cell cycle). Because of dose-rate effects, tumor cells may, in some cases, be more susceptible to the low-dose-rate radiation used in radioimmunotherapy than to the high-dose-rate radiation used in external beam radiotherapy. The efficacy of radioimmunotherapy may potentially be optimized through a variety of approaches, including the use of agents that increase the expression of certain tumor antigens (thus facilitating improved biodistribution of radiolabeled monoclonal antibodies) or that sensitize tumor cells to radiation.
AB - Radioimmunotherapy represents a significant advance over unlabeled immunotherapy for the treatment of patients with B-cell non-Hodgkin's lymphoma. The efficacy of radioimmunotherapeutic agents depends in large part on the basic biological effects associated with their components, monoclonal antibodies and radionuclides, separately and in combination. The radiobiological effects associated with yttrium 90-labeled ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA) include the induction of apoptosis and cell-cycle redistribution (eg, arrest of cells in the G2/M phase of the cell cycle). Because of dose-rate effects, tumor cells may, in some cases, be more susceptible to the low-dose-rate radiation used in radioimmunotherapy than to the high-dose-rate radiation used in external beam radiotherapy. The efficacy of radioimmunotherapy may potentially be optimized through a variety of approaches, including the use of agents that increase the expression of certain tumor antigens (thus facilitating improved biodistribution of radiolabeled monoclonal antibodies) or that sensitize tumor cells to radiation.
UR - http://www.scopus.com/inward/record.url?scp=0346728793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346728793&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2003.10.005
DO - 10.1053/j.seminoncol.2003.10.005
M3 - Article
C2 - 14710397
AN - SCOPUS:0346728793
SN - 0093-7754
VL - 30
SP - 6
EP - 10
JO - Seminars in oncology
JF - Seminars in oncology
IS - 6 SUPPL. 17
ER -